Portada | Volúmenes anteriores

Revista Peruana de Reumatología
© Sociedad Peruana de Reumatología
 ISSN versión electrónica 1609-7181


Rev. peru. reumatol.   2004; 10(3) : 40-41


PATOGÉNESIS DE LA ESCLEROSIS SISTÉMICA

Sonsoles Piera-Velázquez, Chris T. Derk y Sergio A. Jiménez 

BIBLIOGRAFÍA

  1. Feghalí Derk C, Jimenez SA. Followingthe molecular pathways toward an understanding of the pathogenesis of systemic scierosis. Ann Intern Med. 2004J40(1):37-50.

  2. Bostwick C, Medsger TA Jr, Wright TM. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum 2003; 48:1956-63.

  3. Maul GG, Jimenez SA, Riggs E, Ziemnicka-Kotula D.. Determination of an epitope of the diffuse systemic sclerosis marker antigen DNA topoisomerase I: sequence similarity with retroviral p30gag protein suggests a possible cause for autoimmunity in systemic sclerosis. Proc Natl Acad Sci U SA. 1989;86(21):84926.

  4. Jimenez SA, Diaz A, Khalili K. Retroviruses and the pathogenesis of systemic sclerosis. Int Rev Immunol 1995; 12:15975.

  5. Dang H, Dauphinee MJ, Talal N, Garry RF, Seibold IR, Medsger TA Jr, Alexander S, Feghali CA. Serum antibody to retroviral gag proteins in systemic scierosis. Arthritis Rheum 1991; 34:1336-7.

  6. Pandey IP, LeRoy EC. Human cytomegalovirus and the vasculopathies of autoirrimune diseases (especially scleroderma), allograft rejection, and coronary restenosis. Arthritis Rheum 1998; 41:10-15.

  7. Neidhart M, Kuchen S, Disfler O, BruhImann P, Michel BA, Gay RE et al. lncreased serum levels of antibodies against human cytomegalovirus and prevalence of auto-antibodies in systemic scierosis. Arthritis Rheum 1999; 42:3 89-92.

  8. Mayes MD. Epidemiologic studies of environmental agents and systemic autoimmune diseases. Environ Health Perspect 1999; 107 (Suppl 5):743-8.

  9. Diot E, Lesire V, Guilmot JL, Metzger MD, Pilore R, Rogier S, Stadler M, Diot P, Lemarie E, Lasfargues G. Systemic sclerosis and occupational risk factors: a casecontrol study. Occup Environ Med 2002; 59:545-9.

  10. Garabrant DH, Lacey IV ir, Laing TI, Gillespie BW, Mayes MD, Cooper BC, Schottenfeld D. Scleroderma and solvent exposure among women. Am J Epidemiol 2003; 157:493-500.

  11. Johnson RW, Tew MB, Arnett FC. The genetics of systemic sclerosis. Curr Rheumatol Rep 2002; 4:99107.

  12. Reveille JD. Ethnicity and race and systemic sclerosis; how it affects susceptibility, severity, antibody genetics, and clinical manifestations. Curr Rheumatol Rep 2003; 5:160-7.

  13. Hata R, Akai J, Kimura A, Ishikawa O, Kuwana M, Shinkai H et al. Association of functional microsatellites in the human type I collagen a2 chain (COL1A2) gene with systemic sclerosis. Biochem Bíophys Res Com 2000; 272:36-40.

  14. Crilly A, Hamilton J, Clark CJ, Jardine A, Madlok A. Analysis of transforming growth factor b gene polymorphisms in patients with systemic sclerosis. Ann Rheum Dis 2002; 61:678-81.

  15. Artlett CM, Smith JB, Jimenez SA. Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis. N Engl J Med 1998; 338:1186- 91.

  16. Artlett CM. Microchimerísm and scleroderma: an up date. Curr Rheumatol Rep 2003; 5:154-9.

  17. Nelson JL. Microchimerism and HIA relationships of pregnancy: implications for autoimmune diseases. Curr Rheumatol Rep 2001; 3:222-9.

  18. Maloney S, Smith A, Furst DE, Myerson D, Rupert K Evans PC et al. Microchimerism of maternal origin persists into adult life. J Clin Invest 1999; 104:41-47.

  19. Burastero SE, Galbiati S, Vassallo A, Sabbadini MG, Bellone M, Marchionni L, Smid M, Ferrero E, Ferrari A, Ferrari M, Cremonesi L. Cellular microchimerism as a lifelong physiologic status in parous women: an immunologic basis for its amplification in patients with systemic sclerosis. Arthritis Rheum 2003; 48:1109-16.

  20. Ho KT, Reveilleffl. The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther 2003; 5:8093.

  21. Fleischmajer R, Perlish JS, Reeves JR. Cellular infiltrates in scleroderma skin. Arthritis Rheum 1977; 20:975-84.

  22. Jimenez SA. Cellular immune dysfunction and the pathogenesis of scleroderma. Semin Arthritis Rheum 1983; 13(Suppl 1):104-13.

  23. Roumm AD, Whiteside TL, Medsger TA Ir., Rodnan GP. Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum 1984; 27:64553.

  24. Kraling BM, Maul GG, Jimenez SA. Mononuclear cellular infiltrates in clinically involved skin from patients with systemic sclerosis of recent onset predominantly consists of monocytes/macrophages. Pathobiol 1995; 63:48-56.

  25. Chizzolini C. T lymphocyte and fibroblast interactions: the case of skin involvement in systemic sclerosis and other examples. Springer Semin Immunopathol 1999; 21(4): 431-450.

  26. Sakkas LI, Xu B, Artiett CM, Lu S, Jímenez SA, Platsoucas CD. Oligoclonal T cell expansion in the skin of patients with systemic sclerosis. J Immunol 2002; 168:3649-59.

  27. Ferrarini M, Steen V, Medsger TA Ir., Whiteside TL. Functional and phenotypic analysis of T lymphocytes cloned from the skin of patients with systemic sclerosis. Clin Exp Immunol 1990; 79:346-52.

  28. Shirnizu Y, Van Seventer CÍA, Horgan Kj, Shaw S. Regulated expression and binding of three VI-A (bl) integrin receptors on T cells. Nature 1990; 345:250-3.

  29. WhiteB. lmmunopathogenesisofsystemicscierosis. Rheum Dis Clin North Am 1996; 22:695-708.

  30. Postiethwaite AE. Role of T cells and cytokines in effecting fibrosis. Int Rev Immunol 1995;12:247-58.

  31. Varga J, Rosenbloom J, Jimenez SA. Transforming growth factor-b (TGFb) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts. Biochem J 1987; 247:597-604.

  32. lhn H, Yamane K, Kubo M, Tamaki K. Blockade of endogenous transforming growth factor b signaling prevents upregulated collagen synthesis in scleroderma fibrobiasts: association with increased expression of transforming growth factor b receptors. Arthritis Rheum 2001; 44:474-80.

  33. Massague J. How celis read TGF-b signals. Nat Rev Mol Cell Biol 2000; 1: 169-78.

  34. Attisano L, Wrana JL. Signal transduction by the TGF-b superfamily. Science 2002; 296:1646-7.

  35. Varga J. Scleroderma and Smads: dysfunctional Smad family dynamics culminating in fibrosis. Arthritis Rheum 2002; 46:1703 -13.

  36. Dong C, Zhu S, Wang T, Yoon W, Li Z, Alvarezo RS et al. Deficient Smad 7 expression: a putative molecular defect in scleroderma. Proc Natl Acad Sci USA 2002; 99:3908-13.

  37. Leask A, Holmes A, Abraham DJ. Connective tissue growth factor: a newand important player in the pathogenesis of fibrosis. Cun- Rheumatol Rep. 2002; 4:13642.

  38. Jimenez SA, Saitta B. Alterations in the regulation of expression of the alpha 1 (1) collagen gene (COL1 Al) in systemic sclerosis (scleroderma). Springer Semin Immunopathol 1999; 21: 397-414.

  39. Trojanowska M. Molecular aspects of scleroderma. Front Biosci 2002; 7:608-18.

  40. Ghosh AK. Factors involved in the regulation of type I collagen gene expression: implication in fibrosis. Exp Biol Med (Maywood) 2002; 227:301-14.

  41. Hitraya EG, Varga j, Artlett CM, Jimenez SA. ldentification of elements in the promoter of the al(I) procollagen gene involved in its up regulated expression in Systemic Scierosis. Arthritis Rheum 1998; 41:2048-58.

  42. lhn H, Tamaki K. Increased phosphorylation of transcription factor Sp1 in scieroderma fibroblasts: association with increased expression of the type 1 collagen gene. Arthritis Rheum 2000; 43:2240-47.

  43. Gaidarova S, Jimenez SA. Inhibition of al (1) procollagen gene (COL1A1) transcriptional activity by the DNA interactors Mithoxantrone and WP631 in normal and systemic sclerosis dermal fibroblasts. J Biol Chem 2002; 277:38737-45.

  44. Saitta B, Gaidarova S, Cicchillitti L, Jimenez SA. CCAAT binding transcription factor binds and regulates human COL1A1 promoter activity in human dermal fibroblasts. Arthritis Rheum 2000; 43:2219-29.

  45. Kubo M, Czuwara-Ladykowska J, Moussa O, Markiewicz M, Smith E, Silver RM, jablonska S, Blaszczyk M, Watson DK, Trojanowska M. Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scieroderma skin. Am J Pathol. 2003;l 63(2):571-81.

  46. Widom RL, Culic 1, Lee JY, Korn JH. Cioningand characterization of hcKrox, a transcriptional regulator of extracellular matrix gene expression. Gene 1997; 198:40720.

  47. LeRoy EC. Systemic sclerosis. A vascular perspective. Rheum Dis Clin North Am 1,996; 22:695-708.

  48. Drenk F, Deicher HR. Pathophysiological effects of endothelial cytotoxic activity derived from sera of patients with progressive systemic sclerosis. J Rheumato 1988; 15:468-74.

  49. Kahaleh MB, LeRoy EC. Endothelial injury in scleroderma. A protease mechanism. J Lab Clin Med 1983; 101:553-560.

  50. Renaudineau Y, Revelen R, Levy Y, Salojin K, Gilburg B, Shoenfeld Y, Youinc, P. Anti-endothelial cell antibodies in systemic sclerosis. Clin Diagn Lab Immunol. 1999; 6:156-60.

  51. Xu S, Denton CP, Holmes A, Dashwood MR, Abraham DJ, Black CM. Endothelins: effect on matrix biosynthesis and proliferation in normal and scleroderma fibroblasts. J Cardiovasc Pharmacol 1998- Suppl 1: S360-3.

  

Texto completo | Tabla de contenido

Volúmenes anteriores | Listado por Títulos